CROI 2024

CROI 2024
March 03-06, 2024
Denver, Colorado - USA

Conference on Retroviruses and Opportunistic Infections - 31st Annual.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (20)

    Bone Mineral Density in Children With HIV-1 Receiving TAF-Based Antiretroviral Therapy

    • Author(s): Rakhmanina, N
    • descovy
    • genvoya
    • HIV / AIDS
    • Poster

    Longitudinal Analysis of Preexisting Resistance-Associated Mutations Prior to B/F/TAF Switch

    • Author(s): D'Antoni, M
    • biktarvy
    • HIV / AIDS
    • Poster

    Phase 2 Study of Switch to Daily BIC + LEN in Individuals on a Multitablet HIV Treatment Regimen​

    • Author(s): Mounzer, K
    • biktarvy
    • HIV / AIDS
    • Poster

    Antiviral Activity, Safety, and Pharmacokinetics of GS-1720: A Novel Weekly Oral InSTI

    • Author(s): Fichtenbaum, C
    • gs-1720
    • HIV / AIDS
    • Oral

    Preclinical Characterization of GS-5894, A Potent NNRTI With Once-Weekly Oral Dosing Potential

    • Author(s): Lansdon. E
    • gs-5894
    • HIV / AIDS
    • Poster

    Efficacy and Safety of Weekly Islatravir Plus Lenacapavir in PWH at 24 Weeks: A Phase II Study​

    • Author(s): Colson, A
    • sunlenca
    • HIV / AIDS
    • Oral

    Characteristics and Outcomes of Kidney Transplant Patients Hospitalized for COVID-19 in the United States

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19
    • Poster

    Type I IFN Signaling and Regulation in Vesatolimod-Treated Virally Suppressed Adults With HIV-1

    • Author(s): Huang, S
    • vestalimod-(gs-9620)
    • HIV / AIDS
    • Poster

    PrEP Non-Persistence and New HIV Diagnoses: A Real-World Analysis of >120,000 People Prescribed PrEP

    • Author(s): Tao, L
    • descovy-for-prep
    • HIV / AIDS
    • Poster

    Efficacy and Safety of Bulevirtide 2 mg or 10 mg for 96 Weeks in Chronic Hepatitis Delta, Including in 2 PatientsWith HIV/Hepatitis B Virus/Hepatitis Delta Virus

    • Author(s): Wedemeyer, H
    • bulevirtide
    • Liver Diseases
    • Poster

    Discovery of GS-9770 - A Novel Unboosted Once Daily Oral HIV-Protease Inhibitor

    • Author(s): Han, X
    • gs-9770
    • HIV / AIDS
    • Poster

    Lenacapavir Plus bNAbs for People With HIV and Sensitivity to Either Teropavimab or Zinlirvimab

    • Author(s): Eron, J
    • sunlenca
    • HIV / AIDS
    • Oral

    Impact of HIV-1 Capsid Polymorphisms on Viral Fitness and Susceptibility to Lenacapavir

    • Author(s): Hansen, D
    • sunlenca
    • HIV / AIDS
    • Poster

    Racial and Ethnic Disparities in COVID-19 Treatments in the United States

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19
    • Poster

    Remdesivir + Dexamethasone Versus Dexamethasone For the Treatment of COVID-19: Real-World Study in the US

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19
    • Poster

    Remdesivir Reduces Mortality in Immunocompromised Patients Hospitalised for COVID-19 During Omicron

    • Author(s): Mozaffari, E
    • veklury
    • COVID-19
    • Poster

    Effect of Remdesivir on Post-COVID Conditions Among Individuals Hospitalized With COVID-19 By Age

    • Author(s): Berry, M
    • veklury
    • COVID-19
    • Poster

    Phenotyopic Characterization of Replication-Impaired Lenacapavir-Resistant HIV Clinical Isolates

    • Author(s): Demirdjian, S
    • sunlenca
    • HIV / AIDS
    • Poster

    Factors Associated With HBV Response to B/F/TAF Versus DTG + F/TDF at Week 96 in People With Both HIV-1 and HBV

    • Author(s): Avihingsanon, A
    • biktarvy
    • HIV / AIDS
    • Poster

    Lenacapavir Efficacy in CAPELLA Patients With No Fully Active Agents in Optimized Background Regimen

    • Author(s): Ogbuagu, O
    • sunlenca
    • HIV / AIDS
    • Poster